Clinical Trial Update: Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating biweekly ranibizumab (0.5 mg) for exudative age-related macular degeneration with retinal edema unresponsive to anti-VEGF treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Southeast Clinical Research Associates, LLC | Conditions: Exudative Age Related Macular Degeneration | Phase 2 | Status: COMPLETED